Login to Your Account



Most Analysts Like Pharmion Deal

Vidaza, Dacogen Slug It Out; Is Celgene Paying Too Much?

By Randall Osborne


Monday, December 3, 2007
Celgene Corp.'s move last month to acquire Pharmion Corp., paying $2.9 billion in a cash and stock deal that boosted the firm's presence in the worldwide hematology and cancer markets, made perfect sense - but not to everybody. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription